Herein, we evaluated whether ABC abnormalities, documented AHD, or exposure to prior cytotoxic therapy were independently prognostic after accounting for ELN 2022 risk category and TP53 mutation at time of AML presentation. Here, TP53 is linked to mitochondrial DNA depletion syndrome 4a.